Pfizer Inc. reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance. In addition, Pfizer raised its previous 2022 revenue guidance for Comirnaty, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and provided for the first time 2022 revenue guidance for its oral COVID-19 treatment, Paxlovid.
Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth; Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion
Fourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth; Excluding Contributions from Comirnaty and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days Compared to the Prior-Year Quarter
Pfizer provided Full-Year 2022 Record-High Guidance for Revenues of $98.0 to $102.0 Billion and Adjusted Diluted EPS of $6.35 to $6.55, Reflecting 23% and 46% Year-Over-Year Growth at the Midpoints, Respectively
- Raises 2022 Revenue Guidance for Comirnaty to Approximately $32 Billion, Reflecting Doses Expected to be Delivered Under Supply Contracts Signed as of Late-January
- Issues Initial 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Reflecting Treatment Courses Expected to be Delivered Primarily Under Supply Contracts Signed or Committed as of Late- January
